Introduction
Low-dose methotrexate (MTX) has become a commonly used therapeutic option as an anti-inflammatory in the treatment of various autoimmune diseases, including rheumatoid arthritis, lupus, psoriasis and juvenile idiopathic arthritis (Weinblatt et al., 1985; Giannini et al., 1992; Weinblatt et al., 1994; Fortin et al., 2008; Kalb et al., 2009 ).
Despite its widespread use, response to low dose MTX therapy is highly variable and currently unpredictable with failure to achieve disease remission occurring in 40% or more of adult and pediatric arthritis patients (Lambert et al., 2004; Ruperto et al., 2004) .
Hepatic, gastrointestinal and hematological toxicities are commonly reported and often therapy limiting (Weinblatt, 1985; Becker et al., 2010) . In addition, several months of therapy are often required before response can be accurately judged. For patients that fail to respond to MTX therapy, this delay in disease control results in potential disease progression and irreversible joint damage. Thus, early identification of clinical biomarkers that predict optimal response or risk of toxicity will have important clinical implications.
Recent investigations have included genetic, pharmacokinetic and pharmacodynamic markers of response (Halilova et al., 2012) . Notably, the use of erythrocyte measurements of MTX and its polyglutamates has been proposed to reflect both a pharmacokinetic and a pharmacodynamic metric for clinical use (Dervieux et al., 2004; Dervieux et al., 2005) . The importance of the erythrocyte as a pharmacokinetic component of this measurement is reflected in the short plasma half-life of MTX that makes plasma measurements impractical (Kremer et al., 1986) . The pharmacodynamic hypothesis is based on the notion that the polyglutamates of MTX are the biologically This article has not been copyedited and formatted. The final version may differ from this version.
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Metabolism of MTX to its polyglutamated forms has been found to result in increasingly potent inhibition of enzymes of nucleotide biosynthesis, including: thymidylate synthase (TS), phosphoribosylglycinamide formyltransferase (GART), aminoimidazole carboxamide ribonucleotide transformylase (AICART), and amido phosphoribosyltransferase (ATase) (Allegra et al., 1985a; Allegra et al., 1985b; Baram et al., 1988; Sant et al., 1992) . However, such a correlation between MTX polyglutamation and inhibition of these enzymes in a cellular system has not been experimentally evaluated.
To date, biomarker development has been hampered by an incomplete understanding of the mechanism of action of low-dose MTX (Chan and Cronstein, 2010) . The anti-proliferative and anti-inflammatory effects of MTX are believed to be distinct, occurring through the inhibition of different biochemical pathways. Specifically, the anti-proliferative activity of MTX is primarily attributed to inhibition of purine and pyrimidine nucleotide biosynthesis through depletion of intracellular reduced folate cofactors, via inhibition of dihydrofolate reductase (DHFR), and direct inhibition of TS and enzymes of de novo purine biosynthesis, including: ATase, GART and AICART (Borsa and Whitmore, 1969b; Pinedo et al., 1976) . In addition, inhibition of DHFR by MTX results in the cellular accumulation of dihydrofolate (DHF), which also has varying potency in inhibition of these enzymes (Allegra et al., 1985b; Allegra et al., 1987; Baram et al., 1988; Chu et al., 1990; Sant et al., 1992) . The anti-inflammatory mechanism of MTX activity remains controversial, but current evidence supports the inhibition of the purine synthesis pathway through direct inhibition of AICART (Figure 1 ) (Baggott et al., This article has not been copyedited and formatted. The final version may differ from this version.
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JPET #206672 ϳ 1998; Baggott et al., 1999; Morgan et al., 2004; Baggott and Morgan, 2007) . Inhibition of AICART has been found to result in the accumulation of aminoimidazole carboxamide ribotide (ZMP) and its metabolites, which inhibit adenosine deaminase and AMP deaminase resulting in an increase in adenosine and adenine nucleotide levels (Cronstein et al., 1991; Baggott et al., 1993; Morabito et al., 1998) . Elevated levels of extracellular adenosine, through adenosine receptor activation, results in a reduction in inflammation and may depend on MTX polyglutamate formation (Baggott et al., 1986; Cronstein et al., 1993; Urakawa et al., 2000; Dolezalova et al., 2005; You et al., 2013) .
Selective toxicity towards T lymphocytes, and activation of AMP-activated protein kinase (AMPK) by ZMP have also been proposed as mechanisms of activity of MTX in autoimmune disorders (Taisun and Baggott, 1994; Genestier et al., 1998; Fairbanks et al., 1999; Johnston et al., 2005; Beckers et al., 2006; Katerelos et al., 2010) .
Despite experimental evidence that MTX is a potent inhibitor of purified AICART, no study has thoroughly evaluated the exposure-dependent accumulation of ZMP in a cellular system following exposure to MTX. Therefore, a major focus of this study was to understand the relationship between low-dose MTX and the accumulation of this potentially important biochemical in mammalian cells.
Materials and Methods
Cell Culture. K562 cells (erythroblastoid, human, GM05372) were obtained from Coriell Cell Respository (Camden, NJ) and grown in RPMI-1640 medium (Life Sciences, 61870-127) supplemented with 10% fetal bovine serum (Atlanta Biologicals, S11150).
Unless otherwise stated cells were maintained under normal growth conditions in a 37
This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 25, 2013 as DOI: 10.1124 at ASPET Journals on April 9, 2017 jpet.aspetjournals.org Downloaded from JPET #206672 ϴ °C and 5% CO 2 controlled incubator at a density between 2 x 10 5 and 1 x 10 6 cells/mL to maintain cells in a logarithmic growth phase. All experiments were conducted within 6 passages following removal from cryopreservation.
Cell Growth/Cytotoxicity Studies. K562 cells under normal growth conditions were exposed to 1000 nM MTX and monitored over a 96 hour period for changes in cell growth and viability as determined by the trypan blue exclusion assay and routine cell counting on a hemocytometer. In addition, cell growth and cytotoxicity was measured using reagents provided in the Live/Dead® Viability/Cytotoxicity kit (Invitrogen, L-3324). PA/μg protein, reflecting concentration-dependent inhibition of TS. In contrast, intracellular ZMP levels did not display the same exposure-dependent response. In the initial 8 hours of drug exposure, ZMP levels appeared mostly unchanged under all treatment conditions. However, after 24 hours of exposure ZMP levels in the 10, 100
and 1000 nM MTX samples measured 2253 (±199), 103 (± 34) and 19 (± 8) PA/μg protein, respectively. As compared to untreated control ZMP measurements of 19 (±11) PA/μg protein, these measurements represent a 115-and 5-fold increase in ZMP levels following the 10 and 100 nM MTX treatments, respectively, and no change in levels following the 1000 nM MTX.
Pearson pair-wise comparisons between the cellular accumulation of dUMP or ZMP and the accumulation of MTX and its polyglutamates were conducted (Table 1) .
Intracellular levels of dUMP, significantly correlated with total uptake of MTX (MTX-PG total ), however this was not observed for ZMP. In addition, further analysis showed that intracellular levels of dUMP significantly correlated with each of the measured polyglutamate species, most strongly observed with MTX-PG 3 (r=0.81, p<0.001). In contrast, ZMP levels were only moderately correlated with levels of the parent drug (MTX-PG 1 ) (r=0.34, p<0.01) and not to any of the measured polyglutamate species.
Time-and concentration-dependent accumulation of ZMP and dUMP. Given the discordance between MTX effects on ZMP and dUMP accumulation, subsequent studies were designed to elucidate the response over a narrower concentration range with longer exposure times. K562 cells were exposed to MTX concentrations ranging from 1 to 100 nM and untreated control (0 nM MTX) for up to 72 hours. Intracellular levels of ZMP, dUMP and the ratio of the analytes were determined both as a function of concentration and time ( Figure 6 ). Analysis was conducted on a calibrated analytical system allowing for absolute quantification of ZMP and dUMP.
In agreement with the previous set of experiments, ZMP levels were maximal following exposure to 10 nM MTX, and were sustained throughout the 72 hour exposure, reaching levels 170-fold greater than the untreated control (4421 vs. 26 fmole/μg protein). At 5 nM MTX, ZMP levels progressively increased with time reaching a level of 523 fmole/μg protein that was 20-fold greater than control values. In contrast, MTX concentrations greater than 10 nM resulted in an initial increase in ZMP concentrations that subsequently returned to control levels over the 72 hour period of exposure.
Intracellular dUMP levels were also highly responsive to MTX concentration and exposure time. A slight increase in dUMP was observed at the 10 nM MTX concentration reaching levels up to 40-fold greater than the untreated control (1128 vs.
52 fmole/μg protein). The maximum response was observed at 25 nM MTX (15633 fmole/μg protein) and represented a 620-fold increase over control. Interestingly, at concentrations greater than 10 nM MTX, dUMP concentrations continued to increase, reaching a maximum at 48 hr and declining thereafter.
To assess the relative effect of low concentrations of MTX on ZMP and dUMP accumulation, the ratio of intracellular ZMP to dUMP was also determined. Although the maximum ZMP accumulation was observed at the 10 nM MTX concentration, DHF polyglutamate accumulation at low MTX concentrations. To determine the effect of low concentrations of MTX on cellular levels of DHF, K562 cells were exposed to 10 nM MTX for 24 hours and the changes in cellular DHF were determined.
MTX caused a significant increase in DHF to levels 2.9-fold greater than the untreated controls ( Figure 8A ). Furthermore, MTX exposure resulted in a shift in DHF polyglutamation to long-chain polyglutamates, with the weighted average glutamate distribution shifting from a mean (±SD) of 5.52 (±0.05) to 5.95 (±0.08) glutamate residues per molecule of DHF (p < 0.01) ( Figure 8B ). This effect was most pronounced for DHF-PG 6 , which was increased 4.3-fold over control.
Discussion
In this study, exposure of erythroblastoid cells to low concentrations of MTX resulted in the accumulation of the AICART substrate and anti-inflammatory mediator, ZMP. Accumulation of ZMP did not correlate with the formation of MTX polyglutamates and was observed at concentrations below those necessary for inhibition of TS.
Together, these findings substantiate the selective accumulation of ZMP with low-dose MTX and do not support a relationship between levels of MTX polyglutamates and ZMP.
However, the finding that DHF accumulates at low MTX concentrations may be indicative of its role in the selective accumulation of ZMP. These results will be discussed in regard to the biochemical pharmacology of MTX and pharmacodynamic significantly associated with ZMP levels in the cellular system used in this current study (Table 1) . In an intact cellular system, MTX and its polyglutamates as well as endogenous folate inhibitors, such as DHF, would be expected to not only inhibit AICART, but also upstream enzymes in the purine biosynthesis pathway as illustrated in Figure 1 , providing an explanation for the poor correlation between cellular MTX polyglutamate and ZMP concentrations.
Although modest, the correlation between the accumulation of MTX-PG 1 and ZMP suggests that the parent compound may be active in the inhibition of AICART (Table 1) . However, it can be seen that low levels of MTX-PG 2 , MTX-PG 3 and
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Specifically, MTX-PG 1 , MTX-PG 2 and MTX-PG 3 are 11-, 32 and 4-fold more potent inhibitors of TS than AICART, and therefore, low concentrations of MTX would be expected to have an observable effect on dUMP accumulation prior to any detectable effect on ZMP. In contrast, DHF-PG 5 is reported to be 12-fold more potent as an inhibitor of AICART compared to TS, supporting DHF as being responsible for the observed concentration-dependent selectivity of ZMP accumulation at low MTX concentrations (Table 3 conditions. An improved understanding of the complex biochemical pharmacology of MTX will prove paramount in the identification and evaluation of therapeutic biomarkers in the future, and may pave the way for individualization of therapy.
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